发布求助
文献互助 智能选刊 最新文献

Drug Discovery Today最新文献

筛选
英文 中文
Nutrient-transporter driven cytotoxic potential: an emerging nanotherapeutic approach 营养转运蛋白驱动的细胞毒性潜能：一种新兴的纳米治疗方法。
IF 7.5 2区 医学
Drug Discovery Today Pub Date : 2025-09-13 DOI: 10.1016/j.drudis.2025.104478
Sayali Dighe , Namish Manchanda , Shreedhar Sharma, Sanyog Jain
{"title":"Nutrient-transporter driven cytotoxic potential: an emerging nanotherapeutic approach","authors":"Sayali Dighe ,&nbsp;Namish Manchanda ,&nbsp;Shreedhar Sharma,&nbsp;Sanyog Jain","doi":"10.1016/j.drudis.2025.104478","DOIUrl":"10.1016/j.drudis.2025.104478","url":null,"abstract":"<div><div>Malignant cells adapt a metabolic rewiring to maintain their growth and survival. The metabolic landscape is driven by various attributes including genetic mutations, c-Myc and Akt signaling. Moreover, the altered metabolism includes glycolytic flux and overexpressed transporters. Considering the vital role of metabolism in tumorigenesis, distinct transport inhibitors have been identified using <em>in silico</em> and <em>in vitro</em> methods. Unfortunately, the efficacy of such inhibitors has been obscured owing to poor specificity and pharmacokinetics. Given the versatility of nanosystems, research has inclined toward utilizing nanomedicines to target metabolic alterations. This review offers a comprehensive roadmap on recent advances in transporter-targeted nanotherapeutics for cancer management.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 10","pages":"Article 104478"},"PeriodicalIF":7.5,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145068776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Approach Methodologies in Drug Development 药物开发中的新方法和方法论。
IF 7.5 2区 医学
Drug Discovery Today Pub Date : 2025-09-12 DOI: 10.1016/j.drudis.2025.104475
Eckhard von Keutz
{"title":"New Approach Methodologies in Drug Development","authors":"Eckhard von Keutz","doi":"10.1016/j.drudis.2025.104475","DOIUrl":"10.1016/j.drudis.2025.104475","url":null,"abstract":"","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 10","pages":"Article 104475"},"PeriodicalIF":7.5,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145062975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
People analytics and organizational psychology: building a high-performance, innovative culture in the pharmaceutical industry 人员分析与组织心理学：在制药行业建立高效创新的文化。
IF 7.5 2区 医学
Drug Discovery Today Pub Date : 2025-09-12 DOI: 10.1016/j.drudis.2025.104476
Charles H. Jones, Nick Rosemarino, Catarina R. Dolsten
{"title":"People analytics and organizational psychology: building a high-performance, innovative culture in the pharmaceutical industry","authors":"Charles H. Jones,&nbsp;Nick Rosemarino,&nbsp;Catarina R. Dolsten","doi":"10.1016/j.drudis.2025.104476","DOIUrl":"10.1016/j.drudis.2025.104476","url":null,"abstract":"<div><div>Pharmaceutical and biotech organizations advance therapies through a sequence of interdependent stage-gates in which delays, rework, and knowledge discontinuities have outsized economic and patient consequences. Here, we argue that people strategy should be treated as an explicit pipeline–risk control. We introduce the People Analytics + Industrial-Organizational Psychology for R&amp;D, (PA‑IOP‑R&amp;D) framework, which fuses people analytics with organizational psychology to reduce avoidable rework, protect time-to-milestone, and preserve tacit expertise. The framework centers psychological safety (to enable learning, voice, and error reporting in high-uncertainty R&amp;D) and the job demands–resources (JD-R) model (to calibrate resources that buffer high demands and sustain engagement); perceived organizational support provides the reciprocity mechanism that retains scarce late-career know-how. We codify governance guardrails (purpose limitation, transparency, access control, and bias/fairness review) to prevent analytic harms that would otherwise chill voice. We translate leading indicators (e.g., network bottlenecks, demand–resource imbalance, and safety climate) into tested interventions and stage gate-aligned metrics, and specify quasi-experimental evaluation to distinguish signal from noise.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 10","pages":"Article 104476"},"PeriodicalIF":7.5,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145062973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Status and CNS Adverse Drug Report of Sphingosine-1-Phosphate receptor modulators in multiple sclerosis 鞘氨醇-1-磷酸受体调节剂在多发性硬化症中的临床现状及中枢神经系统不良反应报告。
IF 7.5 2区 医学
Drug Discovery Today Pub Date : 2025-09-12 DOI: 10.1016/j.drudis.2025.104469
Ritika Haldar, Abhijit De
{"title":"Clinical Status and CNS Adverse Drug Report of Sphingosine-1-Phosphate receptor modulators in multiple sclerosis","authors":"Ritika Haldar,&nbsp;Abhijit De","doi":"10.1016/j.drudis.2025.104469","DOIUrl":"10.1016/j.drudis.2025.104469","url":null,"abstract":"<div><div>A novel class of immunomodulatory agents like Sphingosine-1-phosphate receptor (S1PR) modulators has appeared as primarily utilized in the management of relapsing forms of multiple sclerosis (MS) by inhibiting lymphocyte egress from lymph node and reducing peripheral T cell encroachment on the CNS. The first accepted oral S1P modulator, Fingolimod has demonstrated significant efficacy in reducing relapse rates and MRI lesion activity in large-scale clinical trials. Subsequent development of more selective agents, such as siponimod, ozanimod, and ponesimod, has further enhanced therapeutic outcomes by minimizing off-target effects while preserving efficacy. In this review, the role of S1PR modulators in MS management, results from clinical trials, associated CNS adverse effects, and their expanding potential have been discussed and summarized.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 10","pages":"Article 104469"},"PeriodicalIF":7.5,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blocking platelet glycoprotein VI (GPVI) as a promising antithrombotic treatment 阻断血小板糖蛋白VI （GPVI）作为一种有前途的抗血栓治疗方法。
IF 7.5 2区 医学
Drug Discovery Today Pub Date : 2025-09-10 DOI: 10.1016/j.drudis.2025.104473
Ruofei Li , Zhiwei Qiu , Yimin Cui , Qian Xiang
{"title":"Blocking platelet glycoprotein VI (GPVI) as a promising antithrombotic treatment","authors":"Ruofei Li ,&nbsp;Zhiwei Qiu ,&nbsp;Yimin Cui ,&nbsp;Qian Xiang","doi":"10.1016/j.drudis.2025.104473","DOIUrl":"10.1016/j.drudis.2025.104473","url":null,"abstract":"<div><div>Glycoprotein VI (GPVI), a key platelet receptor, mediates collagen-induced platelet activation and interacts with fibrin to promote thrombus growth. Studies demonstrate the mechanisms of GPVI in thrombosis, showing its inhibition reduces thrombosis without impairing hemostasis, consistent with the mild bleeding phenotype in GPVI-deficient individuals. GPVI is also implicated in inflammation and cancer. This review introduces the mechanism of GPVI in thrombosis and highlights two investigational GPVI-targeting drugs (glenzocimab and Revacept), summarizing current evidence and future directions for this promising antithrombotic approach.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 10","pages":"Article 104473"},"PeriodicalIF":7.5,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145051666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disruptions in bioactivity driven by dose: a challenge for drug discovery 剂量驱动的生物活性中断：药物发现的挑战。
IF 7.5 2区 医学
Drug Discovery Today Pub Date : 2025-09-10 DOI: 10.1016/j.drudis.2025.104472
David Ramírez-Palma, Karina Martinez-Mayorga
{"title":"Disruptions in bioactivity driven by dose: a challenge for drug discovery","authors":"David Ramírez-Palma,&nbsp;Karina Martinez-Mayorga","doi":"10.1016/j.drudis.2025.104472","DOIUrl":"10.1016/j.drudis.2025.104472","url":null,"abstract":"<div><div>Dose-driven disruptions in bioactivity challenge traditional, structure-focused drug discovery, which often overlooks effects beyond structural factors. Whereas classical dose–response describes quantitative changes in the magnitude of a given effect, evidence shows that many compounds also display biphasic or inverted dose–response profiles and, by extension, dose-dependent shifts in activity type. These phenomena can cause abrupt potency transitions, or even qualitative activity switches, akin to structural activity cliffs, but driven by concentration. Incorporating such effects into activity prediction models (APMs) requires nonlinear modeling, biologically contextualized data sets, and biomacromolecule-focused classification. Recognizing that biological systems exhibit both gradual dose–response behaviors and disruptive, concentration-dependent activity switches will enhance predictive accuracy and guide the development of mechanism-informed drug discovery pipelines.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 10","pages":"Article 104472"},"PeriodicalIF":7.5,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145051583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What future for drug safety? 药物安全的未来如何？
IF 7.5 2区 医学
Drug Discovery Today Pub Date : 2025-09-09 DOI: 10.1016/j.drudis.2025.104467
Lucinda Smith
{"title":"What future for drug safety?","authors":"Lucinda Smith","doi":"10.1016/j.drudis.2025.104467","DOIUrl":"10.1016/j.drudis.2025.104467","url":null,"abstract":"","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 10","pages":"Article 104467"},"PeriodicalIF":7.5,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovative industry perspective: Assessing the proposed regulatory changes and their impact on innovation and competitiveness of the EU regulatory framework as part of the EU General Pharmaceutical Legislation revision 创新行业视角：评估拟议的监管变化及其对欧盟监管框架的创新和竞争力的影响，作为欧盟一般药品立法修订的一部分。
IF 7.5 2区 医学
Drug Discovery Today Pub Date : 2025-09-09 DOI: 10.1016/j.drudis.2025.104468
Sini M. Eskola , Nick Sykes , Sabine Atzor , Gloria Garcia-Palacios , Janina Dzambazoska , Álmath Spooner , Max Rex , Becky Neil , Magda Chlebus , Marie L. De Bruin , Helga Gardarsdottir , Emilie Neez
{"title":"Innovative industry perspective: Assessing the proposed regulatory changes and their impact on innovation and competitiveness of the EU regulatory framework as part of the EU General Pharmaceutical Legislation revision","authors":"Sini M. Eskola ,&nbsp;Nick Sykes ,&nbsp;Sabine Atzor ,&nbsp;Gloria Garcia-Palacios ,&nbsp;Janina Dzambazoska ,&nbsp;Álmath Spooner ,&nbsp;Max Rex ,&nbsp;Becky Neil ,&nbsp;Magda Chlebus ,&nbsp;Marie L. De Bruin ,&nbsp;Helga Gardarsdottir ,&nbsp;Emilie Neez","doi":"10.1016/j.drudis.2025.104468","DOIUrl":"10.1016/j.drudis.2025.104468","url":null,"abstract":"<div><div>This study is the innovative pharmaceutical industry’s assessment on the European Union (EU) General Pharmaceutical Legislation and proposed legislative revisions analysed across seven domains: robustness, patient centricity, predictability, speed, agility, efficiency, and innovator support. Based on interviews, workshops, and literature reviews, the current system is robust, predictable, and patient-centred but lacks agility, efficiency, and speed. The analysed changes included the Regulatory Sandbox, scientific support for combination products, diversification of evidence, and marketing authorisation holder (MAH) involvement in labelling decisions. A Regulatory Sandbox enhances the agility, speed, and innovation of the system. Three concerns weaken the effectiveness of the system: the complexity of providing scientific support for combination products, a lack of flexibility in utilising diverse types of evidence, and the exclusion of MAHs from labelling decisions. Policymakers must address these gaps to achieve a competitive legal framework.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 10","pages":"Article 104468"},"PeriodicalIF":7.5,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advances in computational strategies for allosteric site prediction: Machine learning, molecular dynamics, and network-based approaches 变构位点预测计算策略的最新进展：机器学习、分子动力学和基于网络的方法。
IF 7.5 2区 医学
Drug Discovery Today Pub Date : 2025-09-04 DOI: 10.1016/j.drudis.2025.104466
Jianxiang Huang , Guo Tang , Ning Liu , Xiaolong Li , Shaoyong Lu
{"title":"Recent advances in computational strategies for allosteric site prediction: Machine learning, molecular dynamics, and network-based approaches","authors":"Jianxiang Huang ,&nbsp;Guo Tang ,&nbsp;Ning Liu ,&nbsp;Xiaolong Li ,&nbsp;Shaoyong Lu","doi":"10.1016/j.drudis.2025.104466","DOIUrl":"10.1016/j.drudis.2025.104466","url":null,"abstract":"<div><div>The landscape of allosteric drug discovery is undergoing a transformative shift, driven by the integration of three computational approaches: machine learning (ML), molecular dynamics (MD) simulations, and network theory. ML identifies potential allosteric sites from multidimensional biological datasets; MD simulations, empowered by enhanced sampling algorithms, reveal transient conformational states; and network analyses uncover communication pathways, further aiding in site identification. Their synergy enables rational allosteric modulator design. However, challenges like high computational costs, limited datasets, and model generalizability persist. Future strategies will leverage ML-accelerated MD, open-science data platforms, and advanced ML techniques, including transfer learning with models like AlphaFold and ESM-2. This multidisciplinary approach holds great promise to enhance allosteric drug discovery, driving therapeutic breakthroughs in the post-structural genomics era.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 10","pages":"Article 104466"},"PeriodicalIF":7.5,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantum intelligence in drug discovery: Advancing insights with quantum machine learning 药物发现中的量子智能：利用量子机器学习推进洞察。
IF 7.5 2区 医学
Drug Discovery Today Pub Date : 2025-09-02 DOI: 10.1016/j.drudis.2025.104463
Danishuddin , Md Azizul Haque , Vikas Kumar , Shahper Nazeer Khan , Jong-Joo Kim
{"title":"Quantum intelligence in drug discovery: Advancing insights with quantum machine learning","authors":"Danishuddin ,&nbsp;Md Azizul Haque ,&nbsp;Vikas Kumar ,&nbsp;Shahper Nazeer Khan ,&nbsp;Jong-Joo Kim","doi":"10.1016/j.drudis.2025.104463","DOIUrl":"10.1016/j.drudis.2025.104463","url":null,"abstract":"<div><div>Over recent decades, the pharmaceutical industry has undergone a major transformation with the integration of machine learning (ML) across various stages of the drug discovery pipeline. Although ML has accelerated molecular screening and drug development, it faces critical challenges, such as dependence on large, high-quality datasets, limited interpretability, and increased computational complexity for large systems. Quantum machine learning (QML) has emerged as a powerful alternative, combining quantum computing with artificial intelligence to address these limitations. By harnessing the ability of quantum systems to process high-dimensional data efficiently, QML promises improved accuracy and scalability. This review explores the contributions of QML to drug discovery, focusing on molecular property prediction, docking simulations, <em>de novo</em> design, limitations, ethics, and future directions.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 10","pages":"Article 104463"},"PeriodicalIF":7.5,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信